303
Participants
Start Date
April 30, 1998
Primary Completion Date
September 30, 1998
Study Completion Date
September 30, 1998
biphasic insulin aspart
Injected subcutaneously (under the skin) twice daily
biphasic human insulin
Injected subcutaneously (under the skin) twice daily
Novo Nordisk Investigational Site, Bern
Novo Nordisk Investigational Site, Graz
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Erkner
Novo Nordisk Investigational Site, Schwedt
Novo Nordisk Investigational Site, Anklam
Novo Nordisk Investigational Site, Rostock
Novo Nordisk Investigational Site, Hamburg
Novo Nordisk Investigational Site, Quakenbrück
Novo Nordisk Investigational Site, Neunkirchen
Novo Nordisk Investigational Site, Saarlouis
Novo Nordisk Investigational Site, München
Novo Nordisk Investigational Site, Ulm
Novo Nordisk Investigational Site, Würzburg
Novo Nordisk Investigational Site, Vienna
Novo Nordisk Investigational Site, Cottbus
Novo Nordisk Investigational Site, Jena
Novo Nordisk Investigational Site, Leipzig
Novo Nordisk Investigational Site, Cork
Novo Nordisk Investigational Site, Dublin
Novo Nordisk Investigational Site, Dublin
Novo Nordisk Investigational Site, Ayr
Novo Nordisk Investigational Site, Bath
Novo Nordisk Investigational Site, Birmingham
Novo Nordisk Investigational Site, Blackburn
Novo Nordisk Investigational Site, Bolton
Novo Nordisk Investigational Site, Bristol
Novo Nordisk Investigational Site, Kettering
Novo Nordisk Investigational Site, Leicester
Novo Nordisk Investigational Site, Livingstone
Novo Nordisk Investigational Site, Newcastle
Novo Nordisk Investigational Site, Northampton
Novo Nordisk Investigational Site, Nottingham
Novo Nordisk Investigational Site, Paisley
Novo Nordisk Investigational Site, Watford
Novo Nordisk Investigational Site, Whiston
Lead Sponsor
Novo Nordisk A/S
INDUSTRY